NEW YORK (AP) – Ventrus Biosciences Inc. announced that its most advanced drug failed in two late-stage clinical trials.
Ventrus said its hemorrhoid ointment ifanserin did not work better than a placebo in two studies. The medication was not better than a placebo in eliminating bleeding or stopping itching and pain.
Ventrus said it does not plan to continue development of ifanserin, or VEN 309. The company said it will focus its resources on its other drugs in clinical testing: the anal fissure treatment VEN 307 and fecal incontinence drug VEN 308. Ventrus is a development-stage company and does not have any products on the market.
Date: June 25, 2012
Source: Associated Press
Filed Under: Drug Discovery